Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Tomohisa Otsu

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5030217436, A5071941557. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 8

  1. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  2. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  3. FUT2 and FUT3-specific normalization of DUPAN-2 and carbohydrate antigen 19-9 in preoperative therapy for pancreatic cancer: multicentre retrospective study (G… Co-author DOI 10.1093/bjs/znaf049↗
  4. Phase II Randomized Controlled Trial to Evaluate the Supportive Effect of Koujin (TJ-3020) Powder in Gemcitabine and Nab-Paclitaxel-Treated Unresectable or Rec… Co-author DOI 10.1097/mpa.0000000000002446↗
  5. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.17520↗
  6. Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. Co-author DOI 10.21873/anticanres.17297↗
  7. High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients. Co-author DOI 10.21873/anticanres.16491↗
  8. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15882↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nobuhiko Nakagawa · 6 shared papers, 2024–2026 · strength 1.27
  2. Mitsuro Kanda · 6 shared papers, 2022–2026 · strength 1.14
  3. Masamichi Hayashi · 6 shared papers, 2022–2026 · strength 1.14
  4. Yasuhiro Kodera · 6 shared papers, 2022–2025 · strength 1.12
  5. Keizo Fujita · 4 shared papers, 2024–2026 · strength 0.85
  6. Norifumi Hattori · 4 shared papers, 2022–2025 · strength 0.69
  7. Junpei Yamaguchi · 3 shared papers, 2025–2026 · strength 0.65
  8. Shinji Mii · 2 shared papers, 2026 · strength 0.45
  9. Ryo Ashida · 2 shared papers, 2026 · strength 0.45
  10. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
  11. Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
  12. Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
  13. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  14. Yukihiro Yokoyama · 2 shared papers, 2026 · strength 0.45
  15. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  16. Haruyoshi Tanaka · 2 shared papers, 2025 · strength 0.42
  17. Nobutake Tanaka · 2 shared papers, 2022–2023 · strength 0.29
  18. Atsushi Enomoto · 1 shared paper, 2026 · strength 0.22
  19. Mitsuru Tashiro · 1 shared paper, 2025 · strength 0.22
  20. Masahiro Nakatochi · 1 shared paper, 2025 · strength 0.22
  21. Fuminori Sonohara · 1 shared paper, 2025 · strength 0.22
  22. Masaya Suenaga · 1 shared paper, 2025 · strength 0.20
  23. Toshio Kokuryo · 1 shared paper, 2025 · strength 0.20
  24. Masaki Sunagawa · 1 shared paper, 2025 · strength 0.20
  25. Mina Fukasawa · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.